New definition of metabolic syndrome: Does it have the same cardiovascular risk?;Nueva definición del síndrome metabólico: ¿Mismo riesgo cardiovascular?

Revista Clinica Espanola

Volumn 207, Issue 2, 2007, Pages 69-74

  Rodilla, E ^a   Gonzalez C ^b   Costa, J A ^a   Pascual, J M ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL DE SAGUNTO   (Spain)

Author keywords

C reactive protein; Cardiovascular risk; Metabolic syndrome; Urinary albumin excretion

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY RISK; DIABETIC HYPERTENSION; DIAGNOSTIC TEST; FEMALE; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; METABOLIC SYNDROME X; PROTEIN ANALYSIS;

EID: 33947537177     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13100198     Document Type: Article

References (32)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
4. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-6.
5. Cordero Fort A, Moreno Arribas J, Martín Arnau A, Nasarre Lorite E, Alegría Barrero E, Alegría Ezquerra E. Prevalencia de síndrome metabólico y asociación con la cardiopatía isquémica en pacientes cardiológicos ambulatorios. Rev Clin Esp. 2006;206:259-65.
6. Botella Carretero JI, Fresneda Moreno J, Manzano Espinosa L. Papel de los antagonistas de los receptores de la angiotensina II en el tratamiento del síndrome metabólico. Rev Clin Esp. 2006;206:284-8.
7. Pascual Fuster V, Meco López JF. Nuevos conceptos en el tratamiento dietético del síndrome metabólico. Rev Clin Esp. 2006;206:100-2.
8. Ciria de Pablo C, Pizarro Portillo A, Moreno Palanco MA, Sánchez Luis C, Ibáñez Sanz P, Suárez Fernández C. Evaluación a corto plazo del control de los factores de riesgo y de la prescripción terapéutica en prevención secundaria de enfermedad cardiovascular. Rev Clin Esp. 2005;205:425-9.
9. Grupo ELIPSE. Efectividad en el control de factores de riesgo cardiovascular en diabéticos tipo 2 de la provincia de Ciudad Real. Rev Clin Esp. 2005;205:218-22.
10. Alberti KGMM, Zimmey P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet. 2005;366:1059-62.
11. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289-304.
12. Petrie JC, O'Brien ET, Littler WA, de Swiet M. Recommendations on blood pressure measurement. Br Med J (Clin Res Ed). 1986;293:611-5.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
14. Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem. 1994;40:934-8.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate met hod to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70.
16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26 Suppl 1:S5-20.
17. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16.
18. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93:136-41.
19. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-7.
20. Scuteri A, Najjar S, Morrell C, Lakatta E. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events. Diabetes Care. 2005;28:882-7.
21. Wilson PW. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin North Am. 2004;33:467-81.
22. Rodilla E, García L, Merino C, Costa JA, González C, Pascual JM. Importancia del síndrome metabólico en el control de la presión arterial y de la dislipemia. Med Clin (Barc). 2004;123:601-5.
23. Sone H, Tanaka S, Ishibashi S, Yamasaki Y, Oikawa S, Ito H, et al; Japan Diabetes Complications Study (JDCS) Group. The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions: additional analysis from the Japan Diabetes Complications Study. Diabetes Care. 2006;29:145-7.
24. Lawlor DA, Smith GD, Ebrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia. 2006;49:41-8.
25. Ridker PM, Buring JE, Cook NR, Rifaí N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107: 391-7.
26. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
27. Pascual JM, Rodilla E, González C, Pérez-Hoyos S, Redón J. Long-Term Impact of Systolic Blood Pressure and Glycemia on the Development of Microalbuminuria in Essential Hypertension. Hypertension. 2005;45:1132-7.
28. Rodilla E, Gómez-Belda A, Costa JA, Aragó M, Miralles A, González C, et al. Variaciones de la Proteína C Reactiva con el tratamiento antihipertensivo e hipolipemiante. Med Clin (Barc). 2005;125:561-4.
29. Rodilla E, Costa JA, Mares S, Miralles A, González C, Sánchez C, et al. Importancia de los componentes del síndrome metabólico en los valores de proteína C reactiva. Rev Clin Esp. 2006;206:363-8.
30. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47:1093-100.
31. Gómez-Belda A, Rodilla E, González C, Costa JA, Serra B, Pascual JM. Objetivos del tratamiento hipolipemiante en pacientes con alto riesgo y muy alto riesgo cardiovascular: ¿un reto posible? Rev Clin Esp. 2006;206:417-21.
32. American Diabetes Association. Clinical practice recommendations 2005. Diabetes Care. 2005;28 Suppl 1:S1-79.